ClinicalTrials.gg
CompletedNCT00739973Updated Jun 6, 2011Results posted

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

A Phase 3 interventional study of Placebo and Aliskiren 150 mg tablet in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,694
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.

Enrollment
2nd of 89
2,694 · median 253
Started
2008
with 11 others
Phase 3
38 of 89
none open now
Registered
47th of 89
by date
Lead sponsor
12 of 89
Novartis Pharmaceuticals

Among the 89 studies testing aliskiren in Hypertension, this one is the 2nd largest by enrollment, is one of 12 that started in 2008, is one of 38 in phase 3, and was the 47th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →

About aliskiren

aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 89 studies testing aliskiren in Hypertension as a file.
02

Study summary

Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension, Aliskiren, Amlodipine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • msDBP ≥ 90 mmHg and \< 110 mmHg at the visit prior to Visit 3 (Visit 2 or optional Visit 201)
  • msDBP ≥ 95 mmHg and \< 110 mmHg at Visit 3 (Day 1 / randomization).
  • All patients must have an absolute difference of ≤ 10 mmHg in their msDBP during the last 2 visits of the single-blind run-in period (Visit 2 and 3 or Visits 201 and 3).

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • Pregnant or nursing (lactating) women
  • Women of
  • Previous or current diagnosis of heart failure ( Class II-IV).
  • Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1.
  • Uncontrolled Type 1 or Type 2 diabetes mellitus
  • to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures
  • History of within 5 years
  • History of hypertensive encephalopathy or cerebrovascular accident, or history of (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,694 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.

    Drug: Placebo

  • Experimental
    Aliskiren 150 mg tablet

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Aliskiren 150 mg tablet

  • Experimental
    Aliskiren 300 mg tablet

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Aliskiren 300 mg tablet

  • Experimental
    Amlodipine 5 mg capsule

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Amlodipine 5 mg capsule

  • Experimental
    Amlodipine 10 mg capsule

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg

    Drug: Placebo · Drug: Amlodipine 10 mg capsule

  • Experimental
    Aliskiren/amlodipine 150/5 mg tablet

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Aliskiren/amlodipine 150/5 mg tablet

  • Experimental
    Aliskiren/amlodipine 150/10 mg tablet

    150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Aliskiren/amlodipine 150/10 mg tablet

  • Experimental
    Aliskiren/amlodipine 300/5 mg tablet

    Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Aliskiren/amlodipine 300/5 mg tablet

  • Experimental
    Aliskiren/amlodipine 300/10 mg tablet

    300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.

    Drug: Placebo · Drug: Aliskiren/amlodipine 300/10 mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  2. Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  3. Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  4. Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  5. Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  6. Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  7. Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  8. Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  9. Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  10. Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  11. Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  12. Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  2. Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  3. Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  4. Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  5. Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  6. Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  7. Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  8. Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  9. Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  10. Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  11. Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  12. Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: Baseline to end of study (Week 8)

  13. Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study

    Blood pressure control defined as msSBP \< 140 mm Hg and msDBP \< 90 mm Hg. The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: End of study (Week 8)

  14. Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response

    Blood pressure response in msDBP is defined as a mean sitting diastolic blood pressure \< 90 mmHg or a \>=10 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: End of study (Week 8)

  15. Percentage of Patients Achieving a Successful Systolic Blood Pressure Response

    Blood pressure response in msSBP is defined as a mean sitting systolic blood pressure \< 140 mmHg or a \>= 20 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

    Time frame: End of study (Week 8)

07

Results

Posted May 3, 2011

Participant flow

A total of 2694 patients enrolled in the single-blind, placebo run-in period (2 to 4 weeks) of the study. A total of 1688 patients were randomized into the double-blind treatment period (8 weeks). Three patients were mis-randomized, as they were discontinued from the single-blind period and were not treated in the double-blind period.

Single-blind Period (2 to 4 Weeks)
Participant flow — Single-blind Period (2 to 4 Weeks)
MilestonePlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg Tablet
Started269400000000
Completed168500000000
Not completed100900000000
Withdrew: Adverse event3500000000
Withdrew: Abnormal laboratory value(s)3800000000
Withdrew: Abnormal test procedure result(s)81000000000
Withdrew: Patient withdrew consent8600000000
Withdrew: Lost to follow-up1700000000
Withdrew: Administrative problems1200000000
Withdrew: Protocol deviation1100000000
Double-blind:Randomized Period (8 Weeks)
Participant flow — Double-blind:Randomized Period (8 Weeks)
MilestonePlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg Tablet
Started198195203185181181183178184
Completed168175184173162169170168170
Not completed302019121912131014
Withdrew: Adverse event331273414
Withdrew: Abnormal laboratory values000010010
Withdrew: Abnormal test procedure results110000000
Withdrew: Unsatisfactory therapeutic effect1788422112
Withdrew: Patient no longer needs study drug001000000
Withdrew: Patient withdrew consent424344324
Withdrew: Lost to follow-up024122031
Withdrew: Administrative problems000000100
Withdrew: Protocol deviation531231223
Withdrew: Discont. single-blind, mis- randomized010000200

Outcome measures

SecondaryPairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAliskiren 150 mgAliskiren/Amlodipine 150/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-10.67 ± 1.01-20.64 ± 1.05
Statistical analysis
  • Aliskiren 150 mg vs Aliskiren/Amlodipine 150/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -9.97 · 95% CI -12.81 to -7.12A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAmlodipine 5 mgAliskiren/Amlodipine 150/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-15.82 ± 1.04-20.64 ± 1.05
Statistical analysis
  • Amlodipine 5 mg vs Aliskiren/Amlodipine 150/5 mg · ANCOVA · p = 0.001 · Least square mean difference: -4.82 · 95% CI -7.70 to -1.94A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgPlaceboAliskiren/Amlodipine 150/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)-6.79 ± 1.00-20.64 ± 1.05
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 150/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -13.85 · 95% CI -16.68 to -11.0A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)
mm HgAliskiren 150 mgAliskiren/Amlodipine 150/10 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Systolic Blood Pressure (mssBP)-10.67 ± 1.01-23.87 ± 1.05
Statistical analysis
  • Aliskiren 150 mg vs Aliskiren/Amlodipine 150/10 mg · ANCOVA · p = <0.001 · Least square mean difference: -13.20 · 95% CI -16.04 to -10.4A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren 150 mgAliskiren/Amlodipine 150/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-7.99 ± 0.63-13.98 ± 0.66
Statistical analysis
  • Aliskiren 150 mg vs Aliskiren/Amlodipine 150/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -6.00 · 95% CI -7.77 to -4.22A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAmlodipine 5 mgAliskiren/Amlodipine 150/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-11.0 ± 0.65-13.98 ± 0.66
Statistical analysis
  • Amlodipine 5 mg vs Aliskiren/Amlodipine 150/5 mg · ANCOVA · p = 0.001 · Least square mean difference: -2.98 · 95% CI -4.77 to -1.19A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgPlaceboAliskiren/Amlodipine 150/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-5.35 ± 0.62-13.98 ± 0.66
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 150/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -8.63 · 95% CI -10.39 to -6.87A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren 150 mgAliskiren/Amlodipine 150/10 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-7.99 ± 0.63-16.16 ± 0.66
Statistical analysis
  • Aliskiren 150 mg vs Aliskiren/Amlodipine 150/10 mg · ANCOVA · p = <0.001 · Least square mean difference: -8.17 · 95% CI -9.94 to -6.40A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAmlodipine 10 mgAliskiren/Amlodipine 150/10 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-13.82 ± 0.66-16.16 ± 0.66
Statistical analysis
  • Amlodipine 10 mg vs Aliskiren/Amlodipine 150/10 mg · ANCOVA · p = 0.011 · Least sqaure mean difference: -2.33 · 95% CI -4.14 to -0.53A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgPlaceboAliskiren/Amlodipine 150/10 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-5.35 ± 0.62-16.16 ± 0.66
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 150/10 mg · ANCOVA · p = <0.001 · Least square mean difference: -10.81 · 95% CI -12.57 to -9.05A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren 300 mgAliskiren/Amlodipine 300/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-10.19 ± 0.62-14.99 ± 0.66
Statistical analysis
  • Aliskiren 300 mg vs Aliskiren/Amlodipine 300/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -4.79 · 95% CI -6.56 to -3.03A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAmlodipine 5 mgAliskiren/Amlodipine 300/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-11.0 ± 0.65-14.99 ± 0.66
Statistical analysis
  • Amlodipine 5 mg vs Aliskiren/Amlodipine 300/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -3.98 · 95% CI -5.78 to -2.18A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgPlaceboAliskiren/Amlodipine 300/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-5.35 ± 0.62-14.99 ± 0.66
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 300/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -9.64 · 95% CI -11.41 to -7.87A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren 300 mgAliskiren/Amlodipine 300/10 mg Tablet
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-10.19 ± 0.62-16.45 ± 0.65
Statistical analysis
  • Aliskiren 300 mg vs Aliskiren/Amlodipine 300/10 mg Tablet · ANCOVA · p = <0.001 · Least square mean difference: -6.26 · 95% CI -8.00 to -4.51A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAmlodipine 10 mgAliskiren/Amlodipine 300/10 mg Tablet
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-13.82 ± 0.66-16.45 ± 0.65
Statistical analysis
  • Amlodipine 10 mg vs Aliskiren/Amlodipine 300/10 mg Tablet · ANCOVA · p = 0.004 · Least square mean difference: -2.63 · 95% CI -4.42 to -0.83A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
PrimaryPairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgPlaceboAliskiren/Amlodipine 300/10 mg Tablet
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Diastolic Blood Pressure (msDBP)-5.35 ± 0.62-16.45 ± 0.65
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 300/10 mg Tablet · ANCOVA · p = <0.001 · Least square mean difference: -11.10 · 95% CI -12.85 to -9.35A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAmlodipine 10 mgAliskiren/Amlodipine 150/10 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-21.04 ± 1.05-23.87 ± 1.05
Statistical analysis
  • Amlodipine 10 mg vs Aliskiren/Amlodipine 150/10 mg · ANCOVA · p = 0.056 · Least square mean difference: -2.83 · 95% CI -5.73 to -0.07A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgPlaceboAliskiren/Amlodipine 150/10 mg
Pairwise Comparison of Aliskiren/Amlodipine 150/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)-6.79 ± 1.00-23.87 ± 1.05
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 150/10 mg · ANCOVA · p = <0.001 · Least square mean difference: -17.08 · 95% CI -19.91 to -14.3A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAliskiren 300 mgAliskiren/Amlodipine 300/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-15.37 ± 0.99-21.82 ± 1.06
Statistical analysis
  • Aliskiren 300 mg vs Aliskiren/Amlodipine 300/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -6.45 · 95% CI -9.29 to -3.62A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAmlodipine 5 mgAliskiren/Amlodipine 300/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Amlodipine 5 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-15.82 ± 1.04-21.82 ± 1.06
Statistical analysis
  • Amlodipine 5 mg vs Aliskiren/Amlodipine 300/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -6.00 · 95% CI -8.90 to -3.11A two-way analysis of covariance model with treatment and region asntwo factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgPlaceboAliskiren/Amlodipine 300/5 mg
Pairwise Comparison of Aliskiren/Amlodipine 300/5 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)-6.79 ± 1.00-21.82 ± 1.06
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 300/5 mg · ANCOVA · p = <0.001 · Least square mean difference: -15.03 · 95% CI -17.88 to -12.2
SecondaryPairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAliskiren 300 mgAliskiren/Amlodipine 300/10 mg Tablet
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Aliskiren 300 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-15.37 ± 0.99-23.19 ± 1.04
Statistical analysis
  • Aliskiren 300 mg vs Aliskiren/Amlodipine 300/10 mg Tablet · ANCOVA · p = <0.001 · Least square mean difference: -7.82 · 95% CI -10.63 to -5.02A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAmlodipine 10 mgAliskiren/Amlodipine 300/10 mg Tablet
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Amlodipine 10 mg on Change in Mean Sitting Systolic Blood Pressure (msSBP)-21.04 ± 1.05-23.19 ± 1.04
Statistical analysis
  • Amlodipine 10 mg vs Aliskiren/Amlodipine 300/10 mg Tablet · ANCOVA · p = 0.143 · Least square mean difference: -2.16 · 95% CI -5.04 to 0.73A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. An automated BP measurement device and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgPlaceboAliskiren/Amlodipine 300/10 mg Tablet
Pairwise Comparison of Aliskiren/Amlodipine 300/10 mg vs. Placebo on Change in Mean Sitting Systolic Blood Pressure (msSBP)-6.79 ± 1.00-23.19 ± 1.04
Statistical analysis
  • Placebo vs Aliskiren/Amlodipine 300/10 mg Tablet · ANCOVA · p = <0.001 · Least square mean difference: -16.40 · 95% CI -19.21 to -13.6A two-way analysis of covariance model with treatment and region as two factors, and the baseline as a covariate.
SecondaryPercentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study

Blood pressure control defined as msSBP \< 140 mm Hg and msDBP \< 90 mm Hg. The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of Participants
Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study
Percentage of ParticipantsPlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg Tablet
Percentage of Patients With Blood Pressure Control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at End of Study19.226.936.335.950.349.265.456.568.3
SecondaryPercentage of Patients Achieving a Successful Diastolic Blood Pressure Response

Blood pressure response in msDBP is defined as a mean sitting diastolic blood pressure \< 90 mmHg or a \>=10 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of Participants
Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response
Percentage of ParticipantsPlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg Tablet
Percentage of Patients Achieving a Successful Diastolic Blood Pressure Response34.350.354.262.074.373.283.873.784.7
SecondaryPercentage of Patients Achieving a Successful Systolic Blood Pressure Response

Blood pressure response in msSBP is defined as a mean sitting systolic blood pressure \< 140 mmHg or a \>= 20 mmHg reduction from baseline. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic BP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of Participants
Percentage of Patients Achieving a Successful Systolic Blood Pressure Response
Percentage of ParticipantsPlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg Tablet
Percentage of Patients Achieving a Successful Systolic Blood Pressure Response32.341.553.254.972.167.677.169.780.3

Adverse events

Collected over Baseline to end of study (Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/198 (1%)22/198 (11.1%)
Aliskiren 150 mg Tablet—0/194 (0%)15/194 (7.7%)
Aliskiren 300 mg Tablet—0/203 (0%)18/203 (8.9%)
Amlodipine 5 mg Capsule—1/185 (0.5%)18/185 (9.7%)
Amlodipine 10 mg Capsule—1/181 (0.6%)32/181 (17.7%)
Aliskiren/Amlodipine 150/5 mg Tablet—1/181 (0.6%)15/181 (8.3%)
Aliskiren/Amlodipine 150/10 mg Tablet—2/181 (1.1%)19/181 (10.5%)
Aliskiren/Amlodipine 300/5 mg Tablet—1/178 (0.6%)8/178 (4.5%)
Aliskiren/Amlodipine 300/10 mg Tablet—1/184 (0.5%)30/184 (16.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboAliskiren 150 mg TabletAliskiren 300 mg TabletAmlodipine 5 mg CapsuleAmlodipine 10 mg CapsuleAliskiren/Amlodipine 150/5 mg TabletAliskiren/Amlodipine 150/10 mg TabletAliskiren/Amlodipine 300/5 mg TabletAliskiren/Amlodipine 300/10 mg Tablet
GastroenteritisInfections and infestations0/1980/1940/2030/1850/1810/1810/1811/1780/184
BronchitisInfections and infestations0/1980/1940/2030/1850/1810/1811/1810/1780/184
PneumoniaInfections and infestations0/1980/1940/2031/1851/1810/1810/1810/1780/184
Cerebrovascular accidentNervous system disorders0/1980/1940/2030/1850/1811/1810/1810/1780/184
Calculus uretericRenal and urinary disorders0/1980/1940/2030/1850/1810/1811/1810/1780/184
HydronephrosisRenal and urinary disorders0/1980/1940/2030/1850/1810/1811/1810/1780/184
Retinal detachmentEye disorders0/1980/1940/2030/1850/1810/1810/1810/1781/184
Abdominal massGastrointestinal disorders1/1980/1940/2030/1850/1810/1810/1810/1780/184
Hand fractureInjury, poisoning and procedural complications1/1980/1940/2030/1850/1810/1810/1810/1780/184
Most frequent other events
Most frequent other events
EventPlaceboAliskiren 150 mg TabletAliskiren 300 mg TabletAmlodipine 5 mg CapsuleAmlodipine 10 mg CapsuleAliskiren/Amlodipine 150/5 mg TabletAliskiren/Amlodipine 150/10 mg TabletAliskiren/Amlodipine 300/5 mg TabletAliskiren/Amlodipine 300/10 mg Tablet
Oedema peripheralGeneral disorders2/1982/1943/2038/18525/1814/18114/1812/17825/184
HeadacheNervous system disorders20/19813/19415/20311/1858/18111/1818/1816/1785/184

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg TabletTotal
Mean53.7 ± 10.3254.3 ± 11.0754.0 ± 9.9954.2 ± 11.6155.0 ± 10.3453.9 ± 10.8253.0 ± 10.5954.8 ± 10.2954.4 ± 10.8654.1 ± 10.65
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAliskiren 150 mgAliskiren 300 mgAmlodipine 5 mgAmlodipine 10 mgAliskiren/Amlodipine 150/5 mgAliskiren/Amlodipine 150/10 mgAliskiren/Amlodipine 300/5 mgAliskiren/Amlodipine 300/10 mg TabletTotal
Female108761088694849610078830
Male90119959987978778106858
08

Study locations

18 sites
  • Investigative Site
    East Hanover, New Jersey, United States
  • Investigative Site
    Buenos Aires, Argentina
  • Invesigative Site
    Canberra, Australia
  • Investigative Site
    Toronto, Canada
  • Investigative Site
    Bogota, Colombia
  • Investigative Site
    Copenhagen, Denmark
  • Investigative Site
    Oslo, Finland
  • Investigative Site
    Athens, Greece
  • Investigative Site
    Rome, Italy
  • Investigative Site
    Mexico City, Mexico
  • Investigative Site
    Panama City, Panama
  • Investigative Site
    Lima, Peru
  • Investigative Site
    Bucharest, Romania
  • Investigative Site
    Moscow, Russian Federation
  • Investigative Site
    Pretoria, South Africa
  • Investigative Site
    Madrid, Spain
  • Investigative Site
    Stockholm, Sweden
  • Investigative Site
    Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2008
First posted
Aug 22, 2008
Start
Sep 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
May 3, 2011
Last update
Jun 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00739973
First posted
Aug 22, 2008
Start date
Sep 2008
Primary completion
May 2009
Completion
May 2009
Results posted
May 3, 2011
Last update
Jun 6, 2011

Study contacts

Novartis
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Amlodipine

Start the discussion